Vipoglanstat, CAS 1360622-01-0

Formulation: A solid

Formal Name: 2-[[2,6-dichloro-3-[[(2,2-dimethyl-1-oxopropyl)amino]methyl]phenyl]amino]-6-(2,2-difluoroethoxy)-1-methyl-N-[trans-4-(trifluoromethyl)cyclohexyl]-1H-benzimidazole-5-carboxamide

Purity: ≥98%

Formula Markup: C30H34Cl2F5N5O3

CAS Number: 1360622-01-0

Notes: Vipoglanstat is an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1; IC50 = ≤0.5 nM in isolated human whole blood).{51731} It reduces LPS-induced increases in the influx of neutrophils and levels of cytokines in bronchoalveolar lavage fluid (BALF), as well as the expression of PTGES, the gene encoding mPGES-1, Cox2, and Icam1 in the lung parenchyma, in a human PTGES knock-in mouse model of acute lung injury when administered at a dose of 30 mg/kg.{51732} Vipoglanstat (30 mg/kg) also reduces the lung injury score and expression of PTGES and Nos2, the gene encoding inducible nitric oxide synthase (iNOS), as well as increases survival, in a human PTGES knock-in mouse model of sepsis induced by cecal ligation and puncture. It reduces status epilepticus-induced increases in brain capillary mPGES-1 and P-glycoprotein levels in a human PTGES knock-in mouse model of kainic acid-induced status epilepticus when administered at doses of 10, 30, and 100 mg/kg.{51733}

• SKU: CAY37925-1
• Manufacturer: Cayman Chemical
• Manufacturer SKU: 37925-1
• Package Unit: 1 mg
• Quantity Unit: STK